Jensine Caudill
Adult Health · Ocoee, FLNPI 1114681525
Payments from drug & device makers
Across 103 payments — averaging $38.76 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson$691
- Phathom Pharmaceuticals, Inc.$423
- Madrigal Pharmaceuticals$413
- Takeda Pharmaceuticals U.S.A., Inc.$348
- Ardelyx, Inc.$335
- Lilly USA, LLC$259
- plus $2K from 13 others
What the payments were for
- Food & beverage$3,992100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Johnson & Johnson | 13 | $691 |
| Phathom Pharmaceuticals, Inc. | 8 | $423 |
| Madrigal Pharmaceuticals | 7 | $413 |
| Takeda Pharmaceuticals U.S.A., Inc. | 11 | $348 |
| Ardelyx, Inc. | 8 | $335 |
| Lilly USA, LLC | 3 | $259 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 9 | $247 |
| AbbVie | 15 | $194 |
| Braintree Laboratories, Inc. | 4 | $180 |
| QOL Medical, LLC | 4 | $142 |
| Sanofi | 3 | $136 |
| AstraZeneca | 3 | $132 |
| Novo Nordisk | 3 | $128 |
| GSK | 2 | $114 |
| Regeneron Healthcare Solutions, Inc. | 3 | $76 |
| Mallinckrodt Hospital Products Inc. | 2 | $54 |
| Ipsen Biopharmaceuticals, Inc | 1 | $45 |
| Celltrion USA Inc. | 2 | $41 |
| Pfizer | 2 | $36 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$3,992 in reported general payments places this provider in the 85th percentile of 2,237 adult health providers in Florida.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 41 | $41,146 |
| OzempicSemaglutide | 29 | $33,526 |
| EliquisApixaban | 31 | $23,898 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 20 | $1,508 |
| Atorvastatin Calcium | 129 | $1,015 |
| Levothyroxine Sodium | 95 | $934 |
| Lisinopril | 96 | $832 |
| Rosuvastatin Calcium | 88 | $772 |
| Omeprazole | 73 | $741 |
| Losartan Potassium | 92 | $612 |
| Gabapentin | 31 | $605 |
| Celecoxib | 21 | $580 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 20 | $534 |
| Oxybutynin Chloride | 17 | $511 |
| Carvedilol | 35 | $503 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $128 | $33,52629 claims |
| PfizerEliquis | $36 | $23,89831 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 2,237 adult health providers in Florida.
Other adult health in Ocoee
- Patricia PagnottaMaitland$441K
- Carly KoelschSarasota$265K
- Norma SolisMiami$150K
- Ashley PontenbergWinter Park$136K
- Jeffrey HernandezMiami$122K
- Jamie JohnsonTampa$58K
- Jessica MangesClearwater$52K
- Sita SwamyOrlando$49K
- Alejandro Dela CruzOrlando$44K
- Cynthia OteroMaitland$31K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.